参考文献/References:
[1] AHN E Y,SO M W.The pathogenesis of gout[J].J Rheum Dis,2025,32(1):8-16.
[2] ZHANG F,LIU S,JIN L,et al.Antinociceptive efficacy of retigabine and flupirtine for gout arthritis pain[J].Pharmacology,2020,105(7/8):471-476.
[3] SHIMIZU T,HORI H,UMEYAMA M,et al.Characteristics of gout patients according to the laterality of nephrolithiasis:a cross-sectional study using helical computed tomography[J].Int J Rheum Dis,2019,22(4):567-573.
[4] GHEIT Y,GHEIT I S,IERULLI J,et al.Rare case of gout leading to septic arthritis,osteomyelitis,and septic shock in an elderly patient[J].Cureus,2023,15(11):e48836.
[5] THOTTAM G E,KRASNOKUTSKY S,PILLINGER M H.Gout and metabolic syndrome:a tangled web[J].Curr Rheumatol Rep,2017,19(10):60.
[6] BARDIN T,RICHETTE P.Impact of comorbidities on gout and hyperuricaemia:an update on prevalence and treatment options[J].BMC Med,2017,15(1):123.
[7] ABELES A M,PILLINGER M H.Gout and cardiovascular disease:crystallized confusion[J].Curr Opin Rheumatol,2019,31(2):118-124.
[8] GANCHEVA R,KUNDURDJIEV A,IVANOVA M,et al.Evaluation of cardiovascular risk in stages of gout by a complex multimodal ultrasonography[J].Rheumatol Int,2017,37(1):121-130.
[9] LI S,XU G,LIANG J,et al.The role of advanced imaging in gout management[J].Front Immunol,2021,12:811323.
[10] SUN Z G,WU K X,ULLAH I,et al.Recent advances in xanthine oxidase inhibitors[J].Mini Rev Med Chem,2024,24(12):1177-1186.
[11] WEN S,ARAKAWA H,TAMAI I.Uric acid in health and disease:from physiological functions to pathogenic mechanisms[J].Pharmacol Ther,2024,256:108615.
[12] M?NDEZ-SALAZAR E O,MART?NEZ-NAVA G A.Uric acid extrarenal excretion:the gut microbiome as an evident yet understated factor in gout development[J].Rheumatol Int,2022,42(3):403-412.
[13] WU Y,YE Z,FENG P,et al.Limosilactobacillus fermentum JL-3 isolated from “Jiangshui”ameliorates hyperuricemia by degrading uric acid[J].Gut Microbes,2021,13(1):1-18.
[14] ZHAO H,LU Z,LU Y.The potential of probiotics in the amelioration of hyperuricemia[J].Food Funct,2022,13(5):2394-2414.
[15] KONDRATIUK V E,TARASENKO O M,KARMAZINA O M,et al.Impact of the synbiotics and urate-lowering therapy on gut microbiota and cytokine profile in patients with chronic gouty arthritis[J].J Med Life,2020,13(4):490-498.
[16] YU Y,LIU Q,LI H,et al.Alterations of the gut microbiome associated with the treatment of hyperuricaemia in male rats[J].Front Microbiol,2018,9:2233.
[17] QU Q,DOU Q,XIANG Z,et al.Population-level gut microbiome and its associations with environmental factors and metabolic disorders in Southwest China[J].NPJ Biofilms Microbiomes,2025,11(1):24.
[18] CHU Y,SUN S,HUANG Y,et al.Metagenomic analysis revealed the potential role of gut microbiome in gout[J].NPJ Biofilms Microbiomes,2021,7(1):66.
[19] SHAO T,SHAO L,LI H,et al.Combined signature of the fecal microbiome and metabolome in patients with gout[J].Front Microbiol,2017,8:268.
[20] GUO Z,ZHANG J,WANG Z,et al.Intestinal microbiota distinguish gout patients from healthy humans[J].Sci Rep,2016,6:20602.
[21] KIM H W,YOON E J,JEONG S H,et al.Distinct gut microbiota in patients with asymptomatic hyperuricemia:a potential protector against gout development[J].Yonsei Med J,2022,63(3):241-251.
[22] STOJANOV S,BERLEC A,STRUKELJ B.The influence of probiotics on the Firmicutes/Bacteroidetes ratio in the treatment of obesity and inflammatory bowel disease[J].Microorganisms,2020,8(11):1715.
[23] YAMADA N,IWAMOTO C,KANO H,et al.Evaluation of purine utilization by Lactobacillus gasseri strains with potential to decrease the absorption of food-derived purines in the human intestine[J].Nucleosides Nucleotides Nucleic Acids,2016,35(10/12):670-676.
[24] 金方,杨虹.降血尿酸益生菌株的筛选和降血尿酸机理的探索[J].微生物学通报,2018,45(8):1757-1769.
[25] LI M,YANG D,MEI L,et al.Screening and characterization of purine nucleoside degrading lactic acid bacteria isolated from Chinese sauerkraut and evaluation of the serum uric acid lowering effect in hyperuricemic rats[J].PLoS One,2014,9(9):e105577.
[26] CRANE J K,NAEHER T M,BROOME J E,et al.Role of host xanthine oxidase in infection due to enteropathogenic and Shiga-toxigenic Escherichia coli[J].Infect Immun,2013,81(4):1129-1139.
[27] WANG C H,ZHANG C,XING X H.Metabolic engineering of Escherichia coli cell factory for highly active xanthine dehydrogenase production[J].Bioresour Technol,2017,245(Pt B):1782-1789.
[28] KUO Y W,HSIEH S H,CHEN J F,et al.Lactobacillus reuteri TSR332 and Lactobacillus fermentum TSF331 stabilize serum uric acid levels and prevent hyperuricemia in rats[J].PeerJ,2021,9:e11209.
[29] XI Y,YAN J,LI M,et al.Gut microbiota dysbiosis increases the risk of visceral gout in goslings through translocation of gut-derived lipopolysaccharide[J].Poult Sci,2019,98(11):5361-5373.
[30] SONG N,GAO H,LI J,et al.Microbiota from young mice counteracts susceptibility to age-related gout through modulating butyric acid levels in aged mice[J].Elife,2025,13:RP98714.
[31] LV Q,XU D,ZHANG X,et al.Association of hyperuricemia with immune disorders and intestinal barrier dysfunction[J].Front Physiol,2020,11:524236.
[32] MARTINON F,P?TRILLI V,MAYOR A,et al.Gout-associated uric acid crystals activate the NALP3 inflammasome[J].Nature,2006,440(7081):237-241.
[33] JHANG J J,LIN J H,YEN G C.Beneficial properties of phytochemicals on NLRP3 inflammasome-mediated gout and complication[J].J Agric Food Chem,2018,66(4):765-772.
[34] RAMOS M F P,MONTEIRO DE BARROS A D C M,RAZVICKAS C V,et al.Xanthine oxidase inhibitors and sepsis[J].Int J Immunopathol Pharmacol,2018,32:2058738418772210.
[35] SEO S U,KAMADA N,MU?OZ-PLANILLO R,et al.Distinct commensals induce interleukin-1β via NLRP3 inflammasome in inflammatory monocytes to promote intestinal inflammation in response to injury[J].Immunity,2015,42(4):744-755.
[36] RAN S,CHU M,GU S,et al.Enterococcus faecalis induces apoptosis and pyroptosis of human osteoblastic MG63 cells via the NLRP3 inflammasome[J].Int Endod J,2019,52(1):44-53.
[37] YIN W,LIU S,DONG M,et al.A new NLRP3 inflammasome inhibitor,dioscin,promotes osteogenesis[J].Small,2020,16(1):e1905977.
[38] SIVAPRAKASAM S,PRASAD P D,SINGH N.Benefits of short-chain fatty acids and their receptors in inflammation and carcinogenesis[J].Pharmacol Ther,2016,164:144-151.
[39] TAN J,MCKENZIE C,POTAMITIS M,et al.The role of short-chain fatty acids in health and disease[J].Adv Immunol,2014,121:91-119.
[40] GU Q Y,ZHANG J,FENG Y C.Role of NLRP3 inflammasome in Bifidobacterium longum-regulated visceral hypersensitivity of postinfectious irritable bowel syndrome[J].Artif Cells Nanomed Biotechnol,2016,44(8):1933-1937.
[41] SHAO X,SUN S,ZHOU Y,et al.Bacteroides fragilis restricts colitis-associated cancer via negative regulation of the NLRP3 axis[J].Cancer Lett,2021,523:170-181.
[42] ZI X,SU R,SU R,et al.Elevated serum IL-2 and Th17/Treg imbalance are associated with gout[J].Clin Exp Med,2024,24(1):9.
[43] MANSOUR A A,RAUCCI F,SAVIANO A,et al.Galectin-9 regulates monosodium urate crystal-induced gouty inflammation through the modulation of Treg/Th17 ratio[J].Front Immunol,2021,12:762016.
[44] 杨虹,杨小红,钟晓武,等.辅助性T细胞17/调节性T细胞平衡在原发性痛风性关节炎发病机制中的作用[J].中华风湿病学杂志,2016,20(8):520-525.
[45] GONG T,YANG Y,JIN T,et al.Orchestration of NLRP3 inflammasome activation by ion fluxes[J].Trends Immunol,2018,39(5):393-406.
[46] 王慧,高惠英,李小峰.肠道菌群对痛风免疫机制的影响研究[J].医学综述,2021,27(1):58-62.
[47] CHANG P V,HAO L,OFFERMANNS S,et al.The micro-bial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition[J].Proc Natl Acad Sci U S A,2014,111(6):2247-2252.
[48] SUGAHARA H,ODAMAKI T,FUKUDA S,et al.Probiotic Bifidobacterium longum alters gut luminal metabolism through modification of the gut microbial community[J].Sci Rep,2015,5:13548.
[49] YAMANAKA H,TANIGUCHI A,TSUBOI H,et al.Hypouricaemic effects of yoghurt containing Lactobacillus gasseri PA-3 in patients with hyperuricaemia and/or gout:a randomised,double-blind,placebo-controlled study[J].Mod Rheumatol,2019,29(1):146-150.
[50] NI C,LI X,WANG L,et al.Lactic acid bacteria strains relieve hyperuricaemia by suppressing xanthine oxidase activity via a short-chain fatty acid-dependent mechanism[J].Food Funct,2021,12(15):7054-7067.
[51] LI Y,ZHU J,LIN G,et al.Probiotic effects of Lacticaseibacillus rhamnosus 1155 and Limosilactobacillus fermentum 2644 on hyperuricemic rats[J].Front Nutr,2022,9:993951.
[52] LEE Y,WERLINGER P,SUH J W,et al.Potential probiotic Lacticaseibacillus paracasei MJM60396 prevents hyperuricemia in a multiple way by absorbing purine,suppressing xanthine oxidase and regulating urate excretion in mice[J].Microorganisms,2022,10(5):851.
[53] SANDERS M E.Impact of probiotics on colonizing microbiota of the gut[J].J Clin Gastroenterol,2011,45(Suppl):S115-S119.
[54] SANDERS M E.Probiotics in 2015:their scope and use[J].J Clin Gastroenterol,2015,49(Suppl 1):S2-S6.
[55] KOLIDA S,MEYER D,GIBSON G R.A double-blind placebo-controlled study to establish the bifidogenic dose of inulin in healthy humans[J].Eur J Clin Nutr,2007,61(10):1189-1195.
[56] CANANI R B,COSTANZO M D,LEONE L,et al.Potential beneficial effects of butyrate in intestinal and extraintestinal diseases[J].World J Gastroenterol,2011,17(12):1519-1528.
[57] GIBBONS S M,GURRY T,LAMPE J W,et al.Perspective:leveraging the gut microbiota to predict personalized responses to dietary,prebiotic,and probiotic interventions[J].Adv Nutr,2022,13(5):1450-1461.
[58] BIAN M,WANG J,WANG Y,et al.Chicory ameliorates hyperuricemia via modulating gut microbiota and alleviating LPS/TLR4 axis in quail[J].Biomed Pharmacother,2020,131:110719.
[59] 孟博文,黄传兵.健脾泄浊法对痛风患者肠道微生态的影响及疗效观察[J].风湿病与关节炎,2021,10(2):1-4.
[60] 朱发伟,楼招欢.桑抹茶对高尿酸血症模型大鼠血尿酸水平及肠道菌群的影响[J].中国现代应用药学,2017,34(8):1084-1088.
[61] 李醒,褚夫江,蒋诗林,等.桑黄乙醇提取物对大鼠尿酸代谢及肠道微生物影响的初步研究[J].中国中药杂志,2021,46(1):177-182.
[62] XIE W R,YANG X Y,DENG Z H,et al.Effects of washed microbiota transplantation on serum uric acid levels,symptoms,and intestinal barrier function in patients with acute and recurrent gout:a pilot study[J].Dig Dis,2022,40(5):684-690.
相似文献/References:
[1]邓伟哲,王宏晶,王宇恒,等.微创针刀镜治疗难治性膝关节类风湿关节炎[J].中医正骨,2015,27(11):42.
[2]李艺彬,朱勇,吴昭克.关节镜下多入路全关节滑膜清理术治疗肘关节类风湿关节炎[J].中医正骨,2015,27(11):56.
[3]齐新宇,向黎黎,熊辉,等.基于高蛋白饮食建立鸡痛风性关节炎模型的量效关系研究[J].中医正骨,2015,27(02):1.
QI Xinyu,XIANG Lili,XIONG Hui,et al.A dose-effect relationship study of gouty arthritis chicken model built by high-protein diet[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(08):1.
[4]齐新宇,熊辉,周彪,等.蠲痹历节清方干预鸡急性痛风性关节炎模型的
实验研究[J].中医正骨,2015,27(03):5.
QI Xinyu,XIONG Hui,ZHOU Biao,et al.Juanbilijieqing Fang(蠲痹历节清方)interfere with acute gouty arthritis chiken model[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(08):5.
[5]胡钢锋,肖鲁伟,童培建.关节液代谢组学在类风湿关节炎诊断
及寒热证候分型中的应用[J].中医正骨,2015,27(01):5.
HU Gangfeng,XIAO Luwei,TONG Peijian.Application of joint fluid metabolomics to diagnosis and COLD-HEAT SYMPTOM COMPLEX typing in patients with rheumatoid arthritis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(08):5.
[6]熊辉,曲良烨,向黎黎,等.痛风性关节炎湿热证病证结合模型的建立[J].中医正骨,2014,26(03):14.
Xiong Hui*,Qu Liangye,Xiang Lili,et al.A rat model of gouty arthritis combined with dampness-heat syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(08):14.
[7]孙克民,王平,卢启贵,等.关节镜下滑膜切除术联合中药口服
治疗早期膝关节类风湿关节炎[J].中医正骨,2013,25(09):39.
[8]李峰,郭艳幸,曹向阳,等.贯叶连翘灌胃联合光动力疗法对类风湿关节炎白兔膝关节滑膜组织病理形态的影响[J].中医正骨,2014,26(09):6.
Li Feng*,Guo Yanxing,Cao Xiangyang,et al.Effect of intragastric administration of hypericum perforatum combined with photodynamic therapy on the pathological morphology of synovial tissue of knee joints in rabbits with rheumatoid arthritis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(08):6.
[9]严超,刘喜德,张金禄,等.蜂针疗法治疗膝骨性关节炎的护理[J].中医正骨,2013,25(01):74.
[10]王笑青,张永红,侯宏理,等.顽痹清丸联合非甾体抗炎药及改善病情的抗风湿药治疗湿热痹阻型类风湿关节炎[J].中医正骨,2013,25(03):41.
WANG Xiao-qing*,ZHANG Yong-hong,HOU Hong-li,et al.Curative effect and safety of WANBIQING pills combined with nonsteroidal antiinflammatory drugs and disease modifying antirheumatic drugs in the treatment of rheumatoid arthritis of dampness-heat stagnation type[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(08):41.